SCHEMBL20149436

SCHEMBL20149436

CCOC(O)Cn1c2ccccc2c2nc3nonc3nc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 10/20 0.62
TCF4 P15884 1/20 0.50
TSHR P16473 5/20 0.44
ALDH1A1 P00352 4/20 0.44
HSD17B10 Q99714 4/20 0.44
MAPT P10636 4/20 0.44
USP2 O75604 3/20 0.44
CASP1 P29466 3/20 0.44
CASP7 P55210 3/20 0.44
KDM4E B2RXH2 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
NPC1 O15118 2/20 0.44
HCRTR1 O43613 1/20 0.44
TP53 P04637 1/20 0.44
HPGD P15428 2/20 0.44
SAE1 Q9UBE0 1/20 0.44
UBA2 Q9UBT2 1/20 0.44
TDP1 Q9NUW8 2/20 0.42
POLB P06746 2/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20149529 0.85 CTNNB1 (0.67) CTNNB1TCF4TSHRALDH1A1HSD17B10
SCHEMBL20147874 0.81 CTNNB1 (0.67) CTNNB1TCF4TSHRALDH1A1HSD17B10
SCHEMBL20147881 0.79 CTNNB1 (0.70) CTNNB1TCF4TSHRALDH1A1HSD17B10
SCHEMBL18257902 0.77 CTNNB1 (1.00) CTNNB1TCF4TSHRALDH1A1HSD17B10
SCHEMBL20147886 0.77 CTNNB1 (0.70) CTNNB1TCF4TSHRALDH1A1HSD17B10
SCHEMBL20147884 0.76 CTNNB1 (0.79) CTNNB1TCF4TSHRALDH1A1HSD17B10
SCHEMBL20149481 0.75 CTNNB1 (0.66) CTNNB1TCF4TSHRALDH1A1HSD17B10
SCHEMBL18249656 0.74 CTNNB1 (1.00) CTNNB1TCF4KDM4E
SCHEMBL20147875 0.74 CTNNB1 (0.80) CTNNB1TCF4TSHRALDH1A1HSD17B10
SCHEMBL18257906 0.74 CTNNB1 (1.00) CTNNB1TCF4TSHRALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10273246-B2 Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2019-04-30 US disclosed
US-20180134729-A1 METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS UNIVERSITY OF UTAH 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134729-A1 METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS CTNNB1, CTNNBL1, WNT3A CTNNB1 1/4885TCF4 24/4885TSHR 2937/4885
US-10273246-B2 Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions CTNNB1, CTNNBL1, WNT3A CTNNB1 1/4885TCF4 25/4885TSHR 2920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.